Whitepapers

Sep 22, 2016
Sponsored Content
Hundreds of new vaccines are in clinical development, yet significant barriers to progress exist. These barriers include a lack of novel approaches to help speed timelines and drive efficiencies in clinical testing of vaccines and the need for reduced R&D cost to improve the ROI of vaccine development globally. Read this fact sheet to see how Quintiles’ dedicated team of vaccine experts can help drive your vaccine studies forward.
Sep 21, 2016
Sponsored Content
This paper, which incorporates the results of a survey of 254 pharmaceutical executives worldwide and a range of interviews with industry experts, explores global pharmaceutical companies' growth strategies and their plans for managing the associated risks.
Sep 21, 2016
Sponsored Content
This paper, which incorporates the results of a survey of 254 pharmaceutical executives worldwide and a range of interviews with industry experts, explores global pharmaceutical companies' growth strategies and their plans for managing the associated risks.
Sep 06, 2016
Sponsored Content
In the global life sciences marketplace, the ability to rapidly identify and capitalize on emerging technologies is a critical marker for success. This whitepaper describes how Meta uses world-leading machine intelligence to enable complete, continual, and unbiased awareness of the advances and technologies that will change industries, years in advance.
Sep 01, 2016
Sponsored Content
Many clinical trials rely on clinician-administered assessments, which are subject to variability and error. MedAvante’s research has shown that electronic clinician outcome assessments (eCOA) administered with the Virgil platform demonstrate substantially reduced error rates compared to paper-based assessments. Using eCOA can standardize assessments and reduce error, thereby strengthening signal detection.
Sep 01, 2016
Sponsored Content
Vaccines are one of the most efficacious health investments in history at preventing widespread infectious diseases and reducing human mortality. However, with more than 450 vaccines in development, only one in 10 will reach the populations that need them. You need one global partner to help transform your vaccine development programs. Learn more at www.quintiles.com/vaccines.
Aug 23, 2016
Pharmaceutical Executive
Pharm Exec talks to Mollie Shields-Uehling, a leading advocate for high-assurance identity trust for cyber-transactions in the biopharmaceutical industry. Read our executive summary covering topics like cyber/technical security; eHealth regulatory compliance; work flow automation, the benefits of eSignature programs, and collaboration around key aspects of drug development like the administration of clinical trials and research partnering.
Jul 22, 2016
Pharmaceutical Executive
Drug pricing is a constant hum in the news, begging the question are drug prices really too high? This white paper aims to parse out the real issues at play in the biopharmaceutical market and examine what dynamics are occurring by using oncology in the United States as a case study.
Jul 19, 2016
Sponsored Content
According to Global Genes, more than 350 million people worldwide suffer from rare diseases. Unfortunately, according to the FDA’s Every Life Foundation, only around 5% of rare diseases have a FDA-approved treatment.Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, has worked on more than 245 rare disease studies in 96 countries since 2010. Here, Laurie Witherwax outlines the patient-centric approach that Quintiles deploys to help pharmaceutical and biotechnology companies get new therapies to patients.
Jun 03, 2016
Pharmaceutical Executive
By leveraging co-pay support programs as front-end patient acquisition tactics, marketers can use them as a means of engaging patients in the brand’s integrated and multifaceted marketing stream
native1_300x100
lorem ipsum